RA0251

antibody from Oursmab

Targeting: FGFR2 BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0251

Provider

Oursmab

Product name

Aprutumab (Biosimilar Reference Antibody) (FGFR2)

Antibody type

Monoclonal

Description

Aprutumab is an investigational, fully human monoclonal antibody designed to target the Fibroblast Growth Factor Receptor 2 (FGFR2). It was developed as a potential therapeutic for FGFR2-altered solid tumors, particularly in combination with chemotherapy. Its mechanism involves binding to FGFR2, which is intended to block the binding of fibroblast growth factors (FGFs) and inhibit downstream oncogenic signaling pathways that drive tumor cell proliferation and survival. Clinical development has progressed to Phase II trials, primarily focusing on cancers with specific FGFR2 gene abnormalities.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.